Resources from the same session
119O - Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Presenter: Sibylle Loibl
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA11 - Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
Presenter: Helena Earl
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
117O - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials
Presenter: Valentina Guarneri
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
118O - Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
Presenter: Lucia Del Mastro
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA11 and 117O
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Monica Arnedos
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast